^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

plamotamab (XmAb13676)

i
Other names: XmAb13676, XmAb 13676, CD3 x CD20, CD20 x CD3
Associations
Trials
Company:
Xencor
Drug class:
CD20 inhibitor, CD3 agonist
Related drugs:
Associations
Trials
1d
XmAb13676-01: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies (clinicaltrials.gov)
P1, N=154, Completed, Xencor, Inc. | Active, not recruiting --> Completed | N=270 --> 154 | Trial completion date: Jan 2025 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
plamotamab (XmAb13676)
11ms
Enrollment closed
|
plamotamab (XmAb13676)
over1year
SAFETY AND EFFICACY OF ANTICD20-CD3 BISPECIFIC T-CELL ENGAGING ANTIBODIES IN THE MANAGEMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW OF CLINICAL TRIALS (EHA 2023)
In the trials, mosunetuzumab, glofitamab, epcoritamab, odronextamab, IGM-2323, and plamotamab were identified as antiCD20-CD3 bsAbs, which are evaluated against RRDLBCL as monotherapy and in combination regimens (Table). Based on our analysis , antiCD20-CD3 bsAbs are safe and efficacious. Among these drugs, glofitamab, epcoritamab and odronextamab as monotherapy and/or in combination regimens are the most effective therapies against RRDLBCL. Drug (s) **Author Efficac y ORR, CR per Lugano/RR C for ML criteria **CRS Overall/G 3 per ASTCT/ Lee et al criteria Overall Toxicity G≥3 per CTCAE CNS Toxicity G≥3 Per CTCAE aNHL 35%Mosun IV Budde et al.
Clinical • Review
|
Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • imvotamab (IGM-2323) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab) • plamotamab (XmAb13676)
over1year
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL (clinicaltrials.gov)
P2, N=3, Terminated, Xencor, Inc. | N=240 --> 3 | Trial completion date: Jun 2031 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Dec 2022; The study has been terminated early by the sponsor due to business decision.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
lenalidomide • Monjuvi (tafasitamab-cxix) • plamotamab (XmAb13676)
2years
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis (ASH 2022)
Plamotamab demonstrated evidence of clinical activity in heavily pretreated pts with DLBCL and FL with promising responses in pts with prior CAR-T therapy. CRS was generally manageable with premedication. Safety and efficacy evaluation of pts at the RD is currently ongoing, and updated results will be provided.
Clinical • P1 data
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6)
|
CD20 expression
|
Rituxan (rituximab) • plamotamab (XmAb13676)
over2years
Enrollment open
|
CD19 (CD19 Molecule)
|
lenalidomide • Monjuvi (tafasitamab-cxix) • plamotamab (XmAb13676)
over2years
New P2 trial
|
CD19 (CD19 Molecule)
|
lenalidomide • Monjuvi (tafasitamab-cxix) • plamotamab (XmAb13676)
almost3years
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 mutation
|
Imbruvica (ibrutinib) • plamotamab (XmAb13676)
3years
Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (ASH 2021)
Cytokine release syndrome (CRS) prophylaxis with dexamethasone, antihistamine, and acetaminophen was mandated prior to each administration of plamotamab. Plamotamab demonstrated evidence of clinical activity in heavily pretreated subjects with R/R NHL. CRS was generally manageable with premedication. The study is ongoing with further optimization of dose and schedule.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
dexamethasone • plamotamab (XmAb13676)